RhumbLine Advisers
BIOA

RhumbLine Advisers’s BioAge Labs BIOA Stock Holding History

RhumbLine Advisers’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$618K Buy
35,320
+5,793
+20% +$112K ﹤0.01% 2476
2025
Q4 		$391K Buy
29,527
+875
+3% +$7.76K ﹤0.01% 2816
2025
Q3 		$168K Sell
28,652
-1,484
-5% -$6.95K ﹤0.01% 3314
2025
Q2 		$124K Buy
30,136
+20,336
+208% +$81.9K ﹤0.01% 3453
2025
Q1 		$36.8K Buy
9,800
+5,942
+154% +$27.5K ﹤0.01% 3639
2024
Q4 		$22.3K Buy
+3,858
New +$66.5K ﹤0.01% 3792

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

RhumbLine Advisers's BIOA Position: Q1 2026 in Review

RhumbLine Advisers increased its BioAge Labs (BIOA) stake by 20% in Q1 2026, buying an estimated $112K and bringing the position to 35,320 shares worth $618K. The position accounts for ﹤0.01% of the portfolio, ranked #2476.

RhumbLine Advisers first reported a position in BIOA in Q4 2024 and has held it in 6 quarters since. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • RhumbLine Advisers held 35,320 shares of BioAge Labs worth $618K as of Q1 2026.
  • RhumbLine Advisers bought 5,793 BioAge Labs shares in Q1 2026, an estimated $112K.
  • BioAge Labs made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2476 holding.
  • RhumbLine Advisers first reported a position in BioAge Labs in Q4 2024 and has held it in 6 quarters since.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.